 Home > Active Ingredient News > Antitumor Therapy > Gastric Cancer: The relationship between early tumor response and quality of life in second-line chemotherapy in advanced gastric cancer: an update of the ABSOLUTE study

Gastric Cancer: The relationship between early tumor response and quality of life in second-line chemotherapy in advanced gastric cancer: an update of the ABSOLUTE study

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

apoptosis cancer

water quality meter

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

within the globe,Gastric cancer is the fifth most common malignant tumor and the third leading cause of cancer-related deaths
.

The prognosis of advanced gastric cancer is frustrating

within the globe,Gastric cancer is the fifth most common malignant tumor and the third leading cause of cancer-related deaths

The EuroQol-5 Dimension (EQ-5D) score was used to assess the quality of life of patients with tumor response (CR + PR and PD) at week 8, and the time to tumor progression (TtD)
.

The smallest important difference (MID) is considered to be 0.

The EuroQol-5 Dimension (EQ-5D) score was used to assess the quality of life of patients with tumor response (CR + PR and PD) at week 8, and the time to tumor progression (TtD)

Among the 142 patients in the nab-PTX group, 41 (28.

The CR+PR and PD patients in the nab-PTX group had EQ-5D scores of 0.

Quality of life score

11 out of 41 CR+PR patients in the nab-PTX group (26.
8%) and 7 out of 29 CR+PR patients in the Sb-PTX group (24.
1%), EQ-5D from baseline to week 8 The score exceeds MID
.

Nearly one-third of CR+PR patients in the two groups had improved or no change in their quality of life

11 out of 41 CR+PR patients in the nab-PTX group (26.

MID

The median TtD time of CR+PR and PD patients in the nab-PTX group were 3.
9 and 2.
2 months, respectively (HR=0.
595, 95% CI 0.
358–0.
989); while the median TtD time of CR+PR and PD patients in the Sb-PTX group The time to TtD was 4.
7 and 2.
0 months, respectively (HR = 0.
494, 95% CI 0.
291–0.
841)
.

The median TtD time of CR+PR patients in both groups was longer than that of PD patients

The median TtD time of CR+PR and PD patients in the nab-PTX group were 3.

TtD of two groups

In summary, the second-line application of taxane chemotherapy for advanced gastric cancer, early tumor regression is related to the maintenance of quality of life
.

The second-line application of taxane chemotherapy for advanced gastric cancer, early tumor regression is related to the maintenance of quality of life

Original source:

Fujitani K, Shitara K, Takashima A, et al.
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Gastric Cancer.
2021 Mar;24(2 ):467-476.
doi: 10.
1007/s10120-020-01131-y.
Epub 2020 Nov 2.
Erratum in: Gastric Cancer.
2020 Dec 9;: PMID: 33136231; PMCID: PMC7902565.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.